Jane Street Group LLC Buys 8,918 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Jane Street Group LLC raised its stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 33.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 35,677 shares of the company’s stock after purchasing an additional 8,918 shares during the quarter. Jane Street Group LLC owned 0.11% of Lexeo Therapeutics worth $323,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. BNP Paribas Financial Markets raised its holdings in Lexeo Therapeutics by 184.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock valued at $50,000 after buying an additional 3,591 shares during the last quarter. Values First Advisors Inc. bought a new position in shares of Lexeo Therapeutics during the third quarter valued at about $67,000. MetLife Investment Management LLC boosted its holdings in shares of Lexeo Therapeutics by 121.5% during the third quarter. MetLife Investment Management LLC now owns 14,223 shares of the company’s stock worth $129,000 after purchasing an additional 7,803 shares during the period. Rhumbline Advisers grew its stake in shares of Lexeo Therapeutics by 37.3% in the second quarter. Rhumbline Advisers now owns 13,357 shares of the company’s stock worth $214,000 after purchasing an additional 3,627 shares during the last quarter. Finally, PDT Partners LLC purchased a new position in Lexeo Therapeutics during the 3rd quarter valued at about $241,000. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Price Performance

LXEO opened at $6.82 on Friday. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The company has a market cap of $225.51 million, a price-to-earnings ratio of -2.16 and a beta of 3.08. The stock has a fifty day simple moving average of $7.15 and a two-hundred day simple moving average of $9.97. Lexeo Therapeutics, Inc. has a 12-month low of $5.77 and a 12-month high of $22.33.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Leerink Partners dropped their price objective on Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a report on Wednesday, November 13th. Chardan Capital raised their price target on Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, HC Wainwright boosted their price objective on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday, November 14th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Lexeo Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $23.80.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.